Humulin Nph (Insulin Human)

Humulin Nph is indicated for the management of blood glucose in patients with diabetes mellitus.

• Type 1 diabetes mellitus, as part of a basal insulin regimen.
• Type 2 diabetes mellitus, when basal insulin is required.
• Adjunct to oral antidiabetic agents in type 2 diabetes.
• Use during pregnancy only if the potential benefits outweigh the risks and under medical supervision.
• May be combined with rapid‑acting insulin analogues for intensified insulin therapy.

• Humulin Nph provides insulin human that binds to insulin receptors on cell membranes, activating the receptor’s intrinsic tyrosine kinase activity. This triggers downstream signaling pathways, including the phosphatidylinositol‑3‑kinase (PI3K) cascade, which promotes translocation of glucose transporter type 4 (GLUT4) to the cell surface, enhancing glucose uptake in muscle and adipose tissue and suppressing hepatic glucose production, thereby lowering plasma glucose levels.

Adverse reactions to Humulin Nph can vary in frequency and severity.

Common

• Mild hypoglycemia (low blood sugar).
• Redness, swelling, or bruising at the injection site.
• Localized lipodystrophy (fat tissue changes).
• Gradual weight gain.
• Transient nausea.

Serious

• Severe hypoglycemia with loss of consciousness or seizures.
• Allergic reactions such as urticaria, angioedema, or anaphylaxis.
• Edema or worsening of congestive heart failure.
• Electrolyte disturbances, including hypokalemia.
• Injection‑site infections or abscess formation.

When prescribing or using Humulin Nph, several safety considerations should be observed.

• Monitor blood glucose regularly to adjust dose and avoid hypoglycemia.
• Assess renal and hepatic function, as impairment may alter insulin clearance.
• Use caution in patients with cardiovascular disease or heart failure due to risk of fluid retention.
• Educate patients on proper injection technique to reduce lipodystrophy.
• Review concomitant medications that affect glucose metabolism.
• Pregnant or breastfeeding women should only use under close medical supervision.
• Store the product according to label instructions to maintain potency.

Humulin Nph may interact with other agents that influence blood glucose or insulin action.

Avoid

• Concurrent use of other insulin products without dose adjustment, which can precipitate severe hypoglycemia.
• Beta‑blockers that mask hypoglycemia symptoms.
• High‑dose corticosteroids that raise blood glucose levels.

Use with caution

• Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that increase hypoglycemia risk.
• Diuretics that may affect electrolyte balance.
• ACE inhibitors or ARBs, which can potentiate insulin’s glucose‑lowering effect.
• Alcohol, which can cause unpredictable glucose fluctuations.